Want to see HK:0575 full AI Analyst Report?
Endurance RP (0575) AI Stock Analysis
Endurance RP
(HKEX:0575)
The overall score is low primarily because Endurance RP shows severe and persistent financial weakness, including negative equity, continuing losses and cash burn, with valuation offering limited downside protection and only mildly supportive technicals indicating a neutral, range‑bound trading pattern rather than clear recovery momentum.
Endurance RP (0575) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.72M
- Dividend Yield
- ―
- Average Volume (3M)
- 77.21K
- Price to Earnings (P/E)
- -16.6
- Beta (1Y)
- 0.84
- Revenue Growth
- 489.92%
- EPS Growth
- 62.36%
- Country
- Hong Kong
- Employees
- 17
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Endurance RP Business Overview & Revenue Model
Company Description
Regent Pacific Group Limited is an investment holding company that primarily focuses on the healthcare and life sciences sectors. The company is involved in the research, development, and sale of pharmaceutical products, with a notable focus on treat...
Endurance RP Financial Statement Overview
Summary
Endurance RP’s finances are distressed, with chronic net losses, sharply declining revenue, negative equity, shrinking assets and persistent negative operating cash flow, only partially offset by recent margin and free cash flow improvements.
Income Statement
12Very NegativeBalance Sheet
18Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.42M | 363.00K | 719.00K | 382.00K | 114.00K | 3.25M |
| Gross Profit | 5.02M | -420.00K | -219.00K | -2.34M | -1.11M | 850.00K |
| EBITDA | -896.32K | -4.29M | -4.18M | -7.72M | -9.56M | 10.38M |
| Net Income | -1.95M | -4.71M | -4.48M | -25.05M | -36.43M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 5.73M | 570.92K | 610.00K | 2.79M | 26.32M | 62.23M |
| Cash, Cash Equivalents and Short-Term Investments | 255.96K | 187.97K | 121.00K | 2.42M | 1.41M | 11.13M |
| Total Debt | 7.36M | 3.94M | 3.34M | 1.20M | 13.73M | 14.01M |
| Total Liabilities | 11.78M | 7.21M | 6.51M | 4.35M | 23.72M | 23.46M |
| Stockholders Equity | -6.05M | -6.64M | -5.90M | -1.55M | 2.60M | 38.77M |
Cash Flow | ||||||
| Free Cash Flow | -4.53M | -4.32M | -4.13M | -3.59M | 533.00K | -1.75M |
| Operating Cash Flow | -4.52M | -4.30M | -4.13M | -3.59M | 545.00K | -1.70M |
| Investing Cash Flow | -7,003 | -15.02K | -3,000 | -1,000 | -7,000 | 123.00K |
| Financing Cash Flow | 4.56M | 4.35M | 2.14M | 5.58M | -795.00K | -782.00K |
Endurance RP Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0575, the sentiment is Positive. The current price of 0.87 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.85, and above the 200-day MA of 0.85, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 53.71 is Neutral, neither overbought nor oversold. The STOCH value of 56.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0575.
Endurance RP Peers Comparison
Overall Rating
HK:121775.14Outperform
HK:031052Neutral
HK:012946Neutral- HK:057546Neutral
HK:183542Neutral
HK:033939Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1217 | 75Outperform | HKD 128.02M | -4.54 | -4.90% | ― | -126.01% | -237.50% |
| HK:0310 | 52Neutral | HKD 84.47M | -6.60 | -82.36% | ― | ― | 79.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0129 | 46Neutral | HKD 225.88M | -0.12 | -16.70% | ― | 163.09% | 52.42% |
| HK:0575 | 46Neutral | HKD 253.88M | -16.55 | 30.76% | ― | 489.92% | 62.36% |
| HK:1835 | 42Neutral | HKD 613.36M | -16.61 | -13.47% | ― | 40.35% | -327.36% |
| HK:0339 | 39Underperform | HKD 291.60M | -39.94 | -66.95% | ― | ― | -700.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0575 | Endurance Rp Limited | 0.87 | 0.21 | 31.82% | |
| HK:0129 | Asia Standard International Group | 0.16 | -0.14 | -47.00% | |
| HK:1217 | China Innovation Investment Limited | 0.01 | -0.00 | -28.57% | |
| HK:1835 | Shanghai Realway Capital Assets Management Co., Ltd. Class H | 4.00 | 1.80 | 81.82% | |
| HK:0310 | Prosperity Investment Holdings Limited | 0.14 | -0.10 | -41.88% | |
| HK:0339 | Core Economy Investment Group Limited | 0.68 | 0.52 | 327.22% |
Endurance RP Corporate Events
Regent Pacific’s Deep Longevity to Launch Accrua Telehealth Platform Across U.S.
Regent Pacific’s Deep Longevity unit will launch Accrua, a consumer digital health and telehealth platform, across all 50 U.S. states in October 2026, marking its first large-scale direct-to-consumer push. The service combines online clinician-...
Regent Pacific Secures Milestone Payment as Fosun Readies Senstend Launch in China
Regent Pacific Group has received a US$4.5 million milestone payment from Fosun Wanbang (Jiangsu) Pharmaceutical Group under their licensing and collaboration agreement for Senstend™ in mainland China, reinforcing the strength of their strategi...
Endurance RP lifts profit on China milestone as telehealth and Fortacinâ„¢ expansion advance
Endurance RP reported an unaudited profit of about US$544,000 for the six months to 30 June 2026, driven primarily by a US$5 million milestone from Fosun Wanbang following Chinese approval of Senstend™, partially offset by impairment charges, w...
Regent Pacific Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Regent Pacific Group Limited has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026, along with their release to the market. The board will also consider whether to declare an...
Regent Pacific Signals Return to Profit on Senstend Milestone Payment
Regent Pacific Group Limited has issued a positive profit alert, indicating it expects to post a net profit of between US$0.5 million and US$1 million for the six months ended 30 June 2026, versus a loss of about US$2.22 million a year earlier. Manag...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026